In this paper, genomics and precision medicine have witnessed remarkable progress with the advent of high-throughput sequencing technologies and advances in data analytics. However, because of the data's great dimensionality and complexity, the processing and interpretation of large-scale genomic data present major challenges. In order to overcome these difficulties, this research suggests a novel Intelligent Mutation-Based Evolutionary Optimization Algorithm (IMBOA) created particularly for applications in genomics and precision medicine. In the proposed IMBOA, the mutation operator is guided by genome-based information, allowing for the introduction of variants in candidate solutions that are consistent with known biological processes. The algorithm's combination of Differential Evolution with this intelligent mutation mechanism enables effective exploration and exploitation of the solution space. Applying a domain-specific fitness function, the system evaluates potential solutions for each generation based on genomic correctness and fitness. The fitness function directs the search toward ideal solutions that achieve the problem's objectives, while the genome accuracy measure assures that the solutions have physiologically relevant genomic properties. This work demonstrates extensive tests on diverse genomics datasets, including genotype-phenotype association studies and predictive modeling tasks in precision medicine, to verify the accuracy of the proposed approach. The results demonstrate that, in terms of precision, convergence rate, mean error, standard deviation, prediction, and fitness cost of physiologically important genomic biomarkers, the IMBOA consistently outperforms other cutting-edge optimization methods.
Extraction of lignin via green methods is a crucial step in promoting the bioconversion of lignocellulosic biomasses. In the present study, utilisation of natural deep eutectic solvent for the pretreatment of kenaf fibres biomass is performed. Furthermore, extracted lignin from natural deep eutectic solvent pretreated kenaf biomass was carried out and its comparative study with commercial lignin was studied. The extracted lignin was characterized and investigated through Infrared Fourier transform spectroscopy, X-ray Diffraction, thermogravimetric analysis, UV-Vis spectroscopy, and scanning electron microscopy. FTIR Spectra shows that all samples have almost same set of absorption bands with slight difference in frequencies. CHNS analysis of natural deep eutectic solvent pretreated kenaf fibre showed a slight increase in carbon % from 42.36 to 43.17% and an increase in nitrogen % from - 0.0939 to - 0.1377%. Morphological analysis of commercial lignin shows irregular/uneven surfaces whereas natural deep eutectic solvent extracted lignin shows smooth and wavy surface. EDX analysis indicated noticeable peaks for oxygen and carbon elements which are present in lignocellulosic biomass. Thermal properties showed that lignin is constant at higher temperatures due to more branching and production of extremely condensed aromatic structures. In UV-VIS spectroscopy, commercial lignin shows slightly broad peak between 300 and 400 nm due to presence of carbonyl bond whereas, natural deep eutectic solvent extracted lignin does not show up any peak in this range. XRD results showed that the crystallinity index percentage for kenaf and natural deep eutectic solvent treated kenaf was 70.33 and 69.5% respectively. Therefore, these innovative solvents will undoubtedly have significant impact on the development of clean, green, and sustainable products for biocatalysts, extraction, electrochemistry, adsorption applications.
The generation of food waste (FW) is increasing at an alarming rate, contributing to a total of 32% of all the waste produced globally. Anaerobic digestion (AD) is an effective method for dealing with organic wastes of various compositions, like FW. Waste valorization into value-added products has increased due to the conversion of FW into biogas using AD technology. A variety of pathways are adopted by microbes to avoid unfavorable conditions in AD, including competition between sulfate-reducing bacteria and methane (CH4)-forming bacteria. Anaerobic bacteria decompose organic matter to produce biogas, a digester gas. The composition depends on the type of raw material and the method by which the digestion process is conducted. Studies have shown that the biogas produced by AD contains 65-75% CH4 and 35-45% carbon dioxide (CO2). Methanothrix soehngenii and Methanosaeta concilii are examples of species that convert acetate to CH4 and CO2. Methanobacterium bryantii, Methanobacterium thermoautotrophicum, and Methanobrevibacter arboriphilus are examples of species that produce CH4 from hydrogen and CO2. Methanobacterium formicicum, Methanobrevibacter smithii, and Methanococcus voltae are examples of species that consume formate, hydrogen, and CO2 and produce CH4. The popularity of AD has increased for the development of biorefinery because it is seen as a more environmentally acceptable alternative in comparison to physico-chemical techniques for resource and energy recovery. The review examines the possibility of using accessible FW to produce important value-added products such as organic acids (acetate/butyrate), biopolymers, and other essential value-added products.
Arsenicosis, a syndrome caused by ingestion of arsenic contaminated drinking water, currently affects millions of people in South-East Asia and elsewhere. Previous animal studies revealed that the toxicity of arsenite essentially can be abolished if selenium is co-administered as selenite. Although subsequent studies have provided some insight into the biomolecular basis of this striking antagonism, many details of the biochemical pathways that ultimately result in the detoxification and excretion of arsenic using selenium supplements have yet to be thoroughly studied. To this end and in conjunction with the recent Phase III clinical trial "Selenium in the Treatment of Arsenic Toxicity and Cancers", we have applied synchrotron X-ray techniques to elucidate the mechanisms of this arsenic-selenium antagonism at the tissue and organ levels using an animal model. X-ray fluorescence imaging (XFI) of cryo-dried whole-body sections of laboratory hamsters that had been injected with arsenite, selenite, or both chemical species, provided insight into the distribution of both metalloids 30 minutes after treatment. Co-treated animals showed strong co-localization of arsenic and selenium in the liver, gall bladder and small intestine. X-ray absorption spectroscopy (XAS) of freshly frozen organs of co-treated animals revealed the presence in liver tissues of the seleno bis-(S-glutathionyl) arsinium ion, which was rapidly excreted via bile into the intestinal tract. These results firmly support the previously postulated hepatobiliary excretion of the seleno bis-(S-glutathionyl) arsinium ion by providing the first data pertaining to organs of whole animals.
Acute-on-chronic liver failure (ACLF) is a syndrome that is characterized by the rapid development of organ failures predisposing these patients to a high risk of short-term early death. The main causes of organ failure in these patients are bacterial infections and systemic inflammation, both of which can be severe. For the majority of these patients, a prompt liver transplant is still the only effective course of treatment. Kidneys are one of the most frequent extrahepatic organs that are affected in patients with ACLF, since acute kidney injury (AKI) is reported in 22.8-34% of patients with ACLF. Approach and management of kidney injury could improve overall outcomes in these patients. Importantly, patients with ACLF more frequently have stage 3 AKI with a low rate of response to the current treatment modalities. The objective of the present position paper is to critically review and analyze the published data on AKI in ACLF, evolve a consensus, and provide recommendations for early diagnosis, pathophysiology, prevention, and management of AKI in patients with ACLF. In the absence of direct evidence, we propose expert opinions for guidance in managing AKI in this very challenging group of patients and focus on areas of future research. This consensus will be of major importance to all hepatologists, liver transplant surgeons, and intensivists across the globe.
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set in 2004 on ACLF was published in 2009, and the "APASL ACLF Research Consortium (AARC)" was formed in 2012. The AARC database has prospectively collected nearly 10,500 cases of ACLF from various countries in the Asia-Pacific region. This database has been instrumental in developing the AARC score and grade of ACLF, the concept of the 'Golden Therapeutic Window', the 'transplant window', and plasmapheresis as a treatment modality. Also, the data has been key to identifying pediatric ACLF. The European Association for the Study of Liver-Chronic Liver Failure (EASL CLIF) and the North American Association for the Study of the End Stage Liver Disease (NACSELD) from the West added the concepts of organ failure and infection as precipitants for the development of ACLF and CLIF-Sequential Organ Failure Assessment (SOFA) and NACSELD scores for prognostication. The Chinese Group on the Study of Severe Hepatitis B (COSSH) added COSSH-ACLF criteria to manage hepatitis b virus-ACLF with and without cirrhosis. The literature supports these definitions to be equally effective in their respective cohorts in identifying patients with high mortality. To overcome the differences and to develop a global consensus, APASL took the initiative and invited the global stakeholders, including opinion leaders from Asia, EASL and AASLD, and other researchers in the field of ACLF to identify the key issues and develop an evidence-based consensus document. The consensus document was presented in a hybrid format at the APASL annual meeting in Kyoto in March 2024. The 'Kyoto APASL Consensus' presented below carries the final recommendations along with the relevant background information and areas requiring future studies.
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.